Home
HelpTEST ID FMYO3 MyoMarker 3 Profile
Reporting Name
MyoMarker 3 ProfileSpecimen Type
SerumSpecimen Required
Collection Container/Tube: 10 mL Red
Submission Container/Tube: Plastic vial
Specimen Volume: 5 mL
Acceptable: SST
Collection Instructions: Draw blood in a plain red-top tube(s), serum gel tube is acceptable. Separate serum from cells within 1 hour of collection and send 5 mL of serum refrigerated in a plastic vial.
Specimen Minimum Volume
4 mL (volume does NOT allow for repeat testing)
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 14 days |
| Frozen | 60 days | |
| Ambient | 7 days |
Method Name
Enzyme-linked immunosorbent assay (ELISA); RIPA Gel Radiography
Reject Due To
| Gross hemolysis: | Reject |
| Thawing: | Warm OK; Cold OK |
| Gross lipemia: | Reject |
| Gross icterus | Reject |
| Other: | Anything other than serum; bacterial contamination |
Reference Values
Anti-PL-7 Ab, Anti-PL-12 Ab, Anti-EJ Ab, Anti-OJ Ab, Anti-SRP Ab, Anti-Mi-2-Ab, Anti-U3 RNP (Fibrillarin), Anti-U2 RNP Ab, Anti-Ku Ab:
Reference Range: Negative
Interpretation for:
Anti-Jo-1 Ab, Anti-TIF-1gamma Ab, Anti-MDA-5-Ab (CADM-140), Anti-NXP-2 (P140) Ab, Anti-PM/Scl-100 Ab, Anti-SS-A 52kD Ab IgG, Anti-U1-RNP Ab:
Reference Range: <20
Negative: <20 units
Weak Positive: 20-39 units
Moderate Positive: 40-80 units
Strong Positive: >80 units
Report Available
16 to 25 daysPerforming Laboratory
Esoterix EndocrinologyCPT Code Information
83516 x 9
86235 x 7
Clinical Information
The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of disorders characterized by muscle weakness, resulting from chronic muscle inflammation of unknown cause. Patients with IIM have a variety of autoantibodies with various clinical utilities that fall into two main groups. One group of autoantibodies are found in patients with myositis and are known as Myositis Specific Autoantibodies (MSA). The MSAs are highly specific for patients with polymyositis (PM) dermatomyositis (DM), anti-synthetase syndrome and necrotizing myositis. The second group of autoantibodies are considered Myositis Associated Autoantibodies (MAA). These appear in myositis overlap syndrome and in other connective tissue diseases, which correlate with certain clinical and/or pathophysiological conditions.